1. Home
  2. KLRA vs GENB Comparison

KLRA vs GENB Comparison

Compare KLRA & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kailera Therapeutics Inc. Common Stock

KLRA

Kailera Therapeutics Inc. Common Stock

N/A

Current Price

$11.57

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo Generate Biomedicines Inc. Common Stock

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$10.38

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
KLRA
GENB
Founded
2024
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2026
2026

Fundamental Metrics

Financial Performance
Metric
KLRA
GENB
Price
$11.57
$10.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
★ $43.00
$26.80
AVG Volume (30 Days)
780.6K
★ 869.8K
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.39
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.76
$9.68
52 Week High
$23.82
$22.67

Technical Indicators

Market Signals
Indicator
KLRA
GENB
Relative Strength Index (RSI) 40.01 36.02
Support Level $9.76 N/A
Resistance Level $11.81 $14.33
Average True Range (ATR) 1.01 1.12
MACD -0.18 -0.35
Stochastic Oscillator 5.26 11.30

Price Performance

Historical Comparison
KLRA
GENB

About KLRA Kailera Therapeutics Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: